The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2022

ABSTRACT

Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone mineral density, fatigue, and exercise tolerance of CD patients. Secondly, it also aims to determine the impact of vitamin D supplementation on this population. Detailed Description This will be a clinical, randomized, controlled, and double-blind trial comprising a consecutive sample of 110 CD patients in remission and low serum vitamin D levels treated by the Gastroenterology team of the Inflammatory Intestinal Disease Clinic at the University Hospital (HU/CAS), Federal University of Juiz de Fora (UFJF). These patients will be divided into two groups with 55 patients each. One group will receive vitamin D supplementation (50.000 UI/week) and the other will receive placebo. Upon the approval by the Ethics Committee of the UFJF, the study aims and procedures will be previously explained to the individuals, who will sign an informed consent form. The sample size was based on the handgrip strength test, assuming an alpha risk of 5 % and beta risk of 80 %, standard deviation of 2.5, and a difference in magnitude of 30% of response between intervention and placebo group, the sample size needed was 45 patients in each group. Therefore, considering potential losses, 55 patients will be recruited for each group, requiring a total of 110 volunteers. Study procedure Phase 1. Assessment All patients in the study will be subjected to the following tests: a. clinical assessment; B. biochemical assessment; c. body composition assessment/anthropometry; d. bone mineral density assessment; e. peripheral muscle strength assessment; f. fatigue assessment; g.Exercise Tolerance Testing Clinical Assessment of the Disease The following data will be collected in the initial assessment: age, gender, CD duration, data related to the Montreal Classification (age at the time of diagnosis, disease behavior and location), glucocorticoid use and number of exacerbations in the previous year. The inflammatory activity assessment will be held according to the Harvey-Bradshaw Index, When the score is less than 5, the disease is considered to be inactive. Biochemical Assessment The participants will be instructed to fast 12 hours prior to the blood sampling for analysis. A 5 ml venous blood sample will be collected from the patients in order to determine biochemical parameters. The University Hospital routine laboratory will analyze the venous blood, the levels of C-reactive protein (CRP), calcium, 25-hydroxyvitamin D, parathyroid hormone (PTH) and inflammatory cytokines such as Interleukins (IL) 17, IL 6 and Tumor necrosis factor alfa (TNF-α) . CRP and serum calcium are routinely evaluated in all CD patients under follow-up in the inflammatory bowel disease clinic at HU/CAS. The following reference values will be taken into consideration regarding 25-hydroxyvitamin D: < 20ng/mL = deficiency, between 21 and 29 ng/mL = insufficiency, and > 30 ng/mL = satisfactory. Bone Mineral Density Assessment A bone densitometer, Lunar Prodigy Primo (pr + 351035), will be used to measure the patients' bone mineral density (BMD), expressed in g/cm2, by dual-energy x-ray absorptiometry (DXA). The double-energy X-ray densitometry of the skeleton or specific sites such as the spine and the hip is based on the X-rays absorption by the calcium crystals in the bone. The lumbar spine regions between L1 and L4 and those of the total proximal femur will be assessed. The examination will be held under appropriate conditions, according to the technical quality controls. The coefficient of variation for the lumbar spine and total proximal femur will be obtained based on these results. The low BMD will be defined by the reduction greater than -2.0 standard deviations from the reference value mean of healthy individuals, adjusted according to height, age and gender (Z score), in compliance with the official positions of the International Society for Clinical Densitometry (ISCD). Body Composition Assessment/Anthropometry The assessment will be held through the Quantum BIA (bioelectrical impedance analysis) bioimpedance device. The device is four-pole, has digital display, and provides resistance and reactance values. Total and segmental body composition parameters will be also assessed by DXA expressed in kg. Muscle Strength Assessment The peripheral muscle strength will be assessed through the maximum voluntary handgrip strength using hand-held dynamometry (HHD), which consists of a simple and objective test that estimates the skeletal muscle function. The Jamar's hydraulic dynamometer will be used, since it is recommended by the American Society of Hand Therapists (ASHT) and is considered the most accurate and precise instrument used to assess HHD . Fatigue Assessment The questionnaire by Chalder et al. (Annex), which was validated in Brazil will be applied to assess fatigue. Exercise Tolerance Testing The exercise capacity is assessed by the walking test with progressive loading or Shuttle Walk Test. Phase 2. Intervention A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose. The contraindications and precautions on the use of vitamin D will be respected, namely: hypersensitivity to the D-group vitamins, hypercalcemia, hypercalciuria and metastatic calcification; and interactions with digitalis, thiazides, and anticonvulsant and antacid medications. Despite the possible interference of the skin melanin concentration in vitamin D absorption, no evidence was found to support the differentiated supplementation between Afro descendant and Caucasian individuals. The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D. Throughout the intervention phase, both the treated group and the control group patients will be monitored by phone every 15 days in order to optimize their adhesion. Phase 3. Reassessment At the end of 6 months of supplementation with cholecalciferol (vitamin D3), this subgroup of patients will be subjected to the same assessments performed in phase 1. More... »

URL

https://clinicaltrials.gov/show/NCT02704624

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone mineral density, fatigue, and exercise tolerance of CD patients. Secondly, it also aims to determine the impact of vitamin D supplementation on this population.\n\nDetailed Description\nThis will be a clinical, randomized, controlled, and double-blind trial comprising a consecutive sample of 110 CD patients in remission and low serum vitamin D levels treated by the Gastroenterology team of the Inflammatory Intestinal Disease Clinic at the University Hospital (HU/CAS), Federal University of Juiz de Fora (UFJF). These patients will be divided into two groups with 55 patients each. One group will receive vitamin D supplementation (50.000 UI/week) and the other will receive placebo. Upon the approval by the Ethics Committee of the UFJF, the study aims and procedures will be previously explained to the individuals, who will sign an informed consent form. The sample size was based on the handgrip strength test, assuming an alpha risk of 5 % and beta risk of 80 %, standard deviation of 2.5, and a difference in magnitude of 30% of response between intervention and placebo group, the sample size needed was 45 patients in each group. Therefore, considering potential losses, 55 patients will be recruited for each group, requiring a total of 110 volunteers. Study procedure Phase 1. Assessment All patients in the study will be subjected to the following tests: a. clinical assessment; B. biochemical assessment; c. body composition assessment/anthropometry; d. bone mineral density assessment; e. peripheral muscle strength assessment; f. fatigue assessment; g.Exercise Tolerance Testing Clinical Assessment of the Disease The following data will be collected in the initial assessment: age, gender, CD duration, data related to the Montreal Classification (age at the time of diagnosis, disease behavior and location), glucocorticoid use and number of exacerbations in the previous year. The inflammatory activity assessment will be held according to the Harvey-Bradshaw Index, When the score is less than 5, the disease is considered to be inactive. Biochemical Assessment The participants will be instructed to fast 12 hours prior to the blood sampling for analysis. A 5 ml venous blood sample will be collected from the patients in order to determine biochemical parameters. The University Hospital routine laboratory will analyze the venous blood, the levels of C-reactive protein (CRP), calcium, 25-hydroxyvitamin D, parathyroid hormone (PTH) and inflammatory cytokines such as Interleukins (IL) 17, IL 6 and Tumor necrosis factor alfa (TNF-\u03b1) . CRP and serum calcium are routinely evaluated in all CD patients under follow-up in the inflammatory bowel disease clinic at HU/CAS. The following reference values will be taken into consideration regarding 25-hydroxyvitamin D: < 20ng/mL = deficiency, between 21 and 29 ng/mL = insufficiency, and > 30 ng/mL = satisfactory. Bone Mineral Density Assessment A bone densitometer, Lunar Prodigy Primo (pr + 351035), will be used to measure the patients' bone mineral density (BMD), expressed in g/cm2, by dual-energy x-ray absorptiometry (DXA). The double-energy X-ray densitometry of the skeleton or specific sites such as the spine and the hip is based on the X-rays absorption by the calcium crystals in the bone. The lumbar spine regions between L1 and L4 and those of the total proximal femur will be assessed. The examination will be held under appropriate conditions, according to the technical quality controls. The coefficient of variation for the lumbar spine and total proximal femur will be obtained based on these results. The low BMD will be defined by the reduction greater than -2.0 standard deviations from the reference value mean of healthy individuals, adjusted according to height, age and gender (Z score), in compliance with the official positions of the International Society for Clinical Densitometry (ISCD). Body Composition Assessment/Anthropometry The assessment will be held through the Quantum BIA (bioelectrical impedance analysis) bioimpedance device. The device is four-pole, has digital display, and provides resistance and reactance values. Total and segmental body composition parameters will be also assessed by DXA expressed in kg. Muscle Strength Assessment The peripheral muscle strength will be assessed through the maximum voluntary handgrip strength using hand-held dynamometry (HHD), which consists of a simple and objective test that estimates the skeletal muscle function. The Jamar's hydraulic dynamometer will be used, since it is recommended by the American Society of Hand Therapists (ASHT) and is considered the most accurate and precise instrument used to assess HHD . Fatigue Assessment The questionnaire by Chalder et al. (Annex), which was validated in Brazil will be applied to assess fatigue. Exercise Tolerance Testing The exercise capacity is assessed by the walking test with progressive loading or Shuttle Walk Test. Phase 2. Intervention A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose. The contraindications and precautions on the use of vitamin D will be respected, namely: hypersensitivity to the D-group vitamins, hypercalcemia, hypercalciuria and metastatic calcification; and interactions with digitalis, thiazides, and anticonvulsant and antacid medications. Despite the possible interference of the skin melanin concentration in vitamin D absorption, no evidence was found to support the differentiated supplementation between Afro descendant and Caucasian individuals. The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D. Throughout the intervention phase, both the treated group and the control group patients will be monitored by phone every 15 days in order to optimize their adhesion. Phase 3. Reassessment At the end of 6 months of supplementation with cholecalciferol (vitamin D3), this subgroup of patients will be subjected to the same assessments performed in phase 1.", 
    "endDate": "2022-02-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02704624", 
    "keywords": [
      "serum vitamin", 
      "body composition", 
      "Bone Density", 
      "muscle strength", 
      "exercise tolerance", 
      "fatigue", 
      "inflammatory activity", 
      "Crohn Disease", 
      "randomized controlled trial", 
      "current study", 
      "vitamin D deficiency", 
      "serum calcium", 
      "muscular activity", 
      "patient", 
      "vitamin D supplementation", 
      "population", 
      "double-blind trial", 
      "sample", 
      "remission", 
      "serum vitamin D level", 
      "gastroenterology", 
      "intestinal disease", 
      "University Hospital", 
      "Federal", 
      "placebo", 
      "approval", 
      "ethic committee", 
      "method", 
      "individual", 
      "consent form", 
      "sample size", 
      "alpha", 
      "beta", 
      "standard deviation", 
      "difference", 
      "magnitude", 
      "intervention", 
      "placebo group", 
      "potential loss", 
      "volunteer", 
      "study procedure", 
      "assessment", 
      "clinical assessment", 
      "biochemical assessment", 
      "initial assessment", 
      "age", 
      "Gender Identity", 
      "duration", 
      "classification", 
      "diagnosis", 
      "behavior", 
      "location", 
      "glucocorticoid", 
      "exacerbation", 
      "Harvey", 
      "score", 
      "disease", 
      "blood sampling", 
      "blood sample", 
      "biochemical parameter", 
      "laboratory", 
      "venous blood", 
      "C-reactive protein", 
      "calcium", 
      "25-hydroxyvitamin", 
      "parathyroid hormone", 
      "inflammatory cytokine", 
      "IL", 
      "tumor necrosis", 
      "TNF", 
      "inflammatory bowel disease", 
      "Reference Value", 
      "consideration", 
      "deficiency", 
      "insufficiency", 
      "Bone and Bone", 
      "densitometer", 
      "lunar", 
      "PR", 
      "Photon Absorptiometry", 
      "x-ray", 
      "skeleton", 
      "specific site", 
      "spine", 
      "hip", 
      "absorption", 
      "lumbar spine", 
      "L1", 
      "proximal femur", 
      "examination", 
      "appropriate condition", 
      "technical quality", 
      "coefficient", 
      "variation", 
      "low bone mineral density", 
      "reduction", 
      "healthy individual", 
      "height", 
      "z-score", 
      "compliance", 
      "official", 
      "International Society", 
      "quantum", 
      "bioelectrical impedance analysis", 
      "Equipment and Supply", 
      "pole", 
      "resistance", 
      "reactance", 
      "maximum", 
      "hand", 
      "skeletal muscle function", 
      "dynamometer", 
      "American society", 
      "instrument", 
      "questionnaire", 
      "Annex", 
      "Brazil", 
      "exercise capacity", 
      "loading", 
      "shuttle", 
      "Phase 2", 
      "placebo-controlled study", 
      "Evaluation Study as Topic", 
      "vitamin", 
      "supplementation", 
      "Cholecalciferol", 
      "tablet", 
      "dosage", 
      "IU", 
      "International", 
      "adult", 
      "dose", 
      "malabsorption", 
      "significant loss", 
      "adipose tissue", 
      "single dose", 
      "contraindication", 
      "precaution", 
      "Hypersensitivity", 
      "hypercalcemia", 
      "hypercalciuria", 
      "calcification", 
      "digitalis", 
      "thiazide", 
      "anticonvulsant", 
      "medication", 
      "possible interference", 
      "melanin", 
      "evidence", 
      "descendant", 
      "content", 
      "therapeutic effect", 
      "study completion", 
      "control patient", 
      "complete treatment", 
      "hypovitaminosis", 
      "intervention phase", 
      "treated group", 
      "control group", 
      "phone", 
      "adhesion", 
      "phase 3", 
      "reassessment", 
      "subgroup", 
      "same assessment", 
      "Phase 1"
    ], 
    "name": "The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02704624"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00021.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.411198.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452970.d", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1097/01.mib.0000437614.91258.70", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003898066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2013/153818", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015525669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.5650100211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017061708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ibd.21595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017307514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ibd.22906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019119236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5946/ce.2013.46.4.317", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019987573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jpsychores.2006.10.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038276653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ibd.21300", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039112127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.crohns.2011.02.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040553044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrgastro.2013.31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041241127", 
          "https://doi.org/10.1038/nrgastro.2013.31"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mco.0b013e328357f623", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045929804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-230x-12-47", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048740664", 
          "https://doi.org/10.1186/1471-230x-12-47"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajprenal.00336.2004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053385973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3748/wjg.v20.i17.4934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071370675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5603/ep.2013.0012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073037486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074467244", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02704624"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02704624'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02704624'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02704624'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02704624'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      16 PREDICATES      198 URIs      175 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02704624 schema:about anzsrc-for:3053
2 schema:description Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone mineral density, fatigue, and exercise tolerance of CD patients. Secondly, it also aims to determine the impact of vitamin D supplementation on this population. Detailed Description This will be a clinical, randomized, controlled, and double-blind trial comprising a consecutive sample of 110 CD patients in remission and low serum vitamin D levels treated by the Gastroenterology team of the Inflammatory Intestinal Disease Clinic at the University Hospital (HU/CAS), Federal University of Juiz de Fora (UFJF). These patients will be divided into two groups with 55 patients each. One group will receive vitamin D supplementation (50.000 UI/week) and the other will receive placebo. Upon the approval by the Ethics Committee of the UFJF, the study aims and procedures will be previously explained to the individuals, who will sign an informed consent form. The sample size was based on the handgrip strength test, assuming an alpha risk of 5 % and beta risk of 80 %, standard deviation of 2.5, and a difference in magnitude of 30% of response between intervention and placebo group, the sample size needed was 45 patients in each group. Therefore, considering potential losses, 55 patients will be recruited for each group, requiring a total of 110 volunteers. Study procedure Phase 1. Assessment All patients in the study will be subjected to the following tests: a. clinical assessment; B. biochemical assessment; c. body composition assessment/anthropometry; d. bone mineral density assessment; e. peripheral muscle strength assessment; f. fatigue assessment; g.Exercise Tolerance Testing Clinical Assessment of the Disease The following data will be collected in the initial assessment: age, gender, CD duration, data related to the Montreal Classification (age at the time of diagnosis, disease behavior and location), glucocorticoid use and number of exacerbations in the previous year. The inflammatory activity assessment will be held according to the Harvey-Bradshaw Index, When the score is less than 5, the disease is considered to be inactive. Biochemical Assessment The participants will be instructed to fast 12 hours prior to the blood sampling for analysis. A 5 ml venous blood sample will be collected from the patients in order to determine biochemical parameters. The University Hospital routine laboratory will analyze the venous blood, the levels of C-reactive protein (CRP), calcium, 25-hydroxyvitamin D, parathyroid hormone (PTH) and inflammatory cytokines such as Interleukins (IL) 17, IL 6 and Tumor necrosis factor alfa (TNF-α) . CRP and serum calcium are routinely evaluated in all CD patients under follow-up in the inflammatory bowel disease clinic at HU/CAS. The following reference values will be taken into consideration regarding 25-hydroxyvitamin D: < 20ng/mL = deficiency, between 21 and 29 ng/mL = insufficiency, and > 30 ng/mL = satisfactory. Bone Mineral Density Assessment A bone densitometer, Lunar Prodigy Primo (pr + 351035), will be used to measure the patients' bone mineral density (BMD), expressed in g/cm2, by dual-energy x-ray absorptiometry (DXA). The double-energy X-ray densitometry of the skeleton or specific sites such as the spine and the hip is based on the X-rays absorption by the calcium crystals in the bone. The lumbar spine regions between L1 and L4 and those of the total proximal femur will be assessed. The examination will be held under appropriate conditions, according to the technical quality controls. The coefficient of variation for the lumbar spine and total proximal femur will be obtained based on these results. The low BMD will be defined by the reduction greater than -2.0 standard deviations from the reference value mean of healthy individuals, adjusted according to height, age and gender (Z score), in compliance with the official positions of the International Society for Clinical Densitometry (ISCD). Body Composition Assessment/Anthropometry The assessment will be held through the Quantum BIA (bioelectrical impedance analysis) bioimpedance device. The device is four-pole, has digital display, and provides resistance and reactance values. Total and segmental body composition parameters will be also assessed by DXA expressed in kg. Muscle Strength Assessment The peripheral muscle strength will be assessed through the maximum voluntary handgrip strength using hand-held dynamometry (HHD), which consists of a simple and objective test that estimates the skeletal muscle function. The Jamar's hydraulic dynamometer will be used, since it is recommended by the American Society of Hand Therapists (ASHT) and is considered the most accurate and precise instrument used to assess HHD . Fatigue Assessment The questionnaire by Chalder et al. (Annex), which was validated in Brazil will be applied to assess fatigue. Exercise Tolerance Testing The exercise capacity is assessed by the walking test with progressive loading or Shuttle Walk Test. Phase 2. Intervention A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose. The contraindications and precautions on the use of vitamin D will be respected, namely: hypersensitivity to the D-group vitamins, hypercalcemia, hypercalciuria and metastatic calcification; and interactions with digitalis, thiazides, and anticonvulsant and antacid medications. Despite the possible interference of the skin melanin concentration in vitamin D absorption, no evidence was found to support the differentiated supplementation between Afro descendant and Caucasian individuals. The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D. Throughout the intervention phase, both the treated group and the control group patients will be monitored by phone every 15 days in order to optimize their adhesion. Phase 3. Reassessment At the end of 6 months of supplementation with cholecalciferol (vitamin D3), this subgroup of patients will be subjected to the same assessments performed in phase 1.
3 schema:endDate 2022-02-01T00:00:00Z
4 schema:keywords 25-hydroxyvitamin
5 American society
6 Annex
7 Bone Density
8 Bone and Bone
9 Brazil
10 C-reactive protein
11 Cholecalciferol
12 Crohn Disease
13 Equipment and Supply
14 Evaluation Study as Topic
15 Federal
16 Gender Identity
17 Harvey
18 Hypersensitivity
19 IL
20 IU
21 International
22 International Society
23 L1
24 PR
25 Phase 1
26 Phase 2
27 Photon Absorptiometry
28 Reference Value
29 TNF
30 University Hospital
31 absorption
32 adhesion
33 adipose tissue
34 adult
35 age
36 alpha
37 anticonvulsant
38 appropriate condition
39 approval
40 assessment
41 behavior
42 beta
43 biochemical assessment
44 biochemical parameter
45 bioelectrical impedance analysis
46 blood sample
47 blood sampling
48 body composition
49 calcification
50 calcium
51 classification
52 clinical assessment
53 coefficient
54 complete treatment
55 compliance
56 consent form
57 consideration
58 content
59 contraindication
60 control group
61 control patient
62 current study
63 deficiency
64 densitometer
65 descendant
66 diagnosis
67 difference
68 digitalis
69 disease
70 dosage
71 dose
72 double-blind trial
73 duration
74 dynamometer
75 ethic committee
76 evidence
77 exacerbation
78 examination
79 exercise capacity
80 exercise tolerance
81 fatigue
82 gastroenterology
83 glucocorticoid
84 hand
85 healthy individual
86 height
87 hip
88 hypercalcemia
89 hypercalciuria
90 hypovitaminosis
91 individual
92 inflammatory activity
93 inflammatory bowel disease
94 inflammatory cytokine
95 initial assessment
96 instrument
97 insufficiency
98 intervention
99 intervention phase
100 intestinal disease
101 laboratory
102 loading
103 location
104 low bone mineral density
105 lumbar spine
106 lunar
107 magnitude
108 malabsorption
109 maximum
110 medication
111 melanin
112 method
113 muscle strength
114 muscular activity
115 official
116 parathyroid hormone
117 patient
118 phase 3
119 phone
120 placebo
121 placebo group
122 placebo-controlled study
123 pole
124 population
125 possible interference
126 potential loss
127 precaution
128 proximal femur
129 quantum
130 questionnaire
131 randomized controlled trial
132 reactance
133 reassessment
134 reduction
135 remission
136 resistance
137 same assessment
138 sample
139 sample size
140 score
141 serum calcium
142 serum vitamin
143 serum vitamin D level
144 shuttle
145 significant loss
146 single dose
147 skeletal muscle function
148 skeleton
149 specific site
150 spine
151 standard deviation
152 study completion
153 study procedure
154 subgroup
155 supplementation
156 tablet
157 technical quality
158 therapeutic effect
159 thiazide
160 treated group
161 tumor necrosis
162 variation
163 venous blood
164 vitamin
165 vitamin D deficiency
166 vitamin D supplementation
167 volunteer
168 x-ray
169 z-score
170 schema:name The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial
171 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02704624
172 schema:sdDatePublished 2019-03-07T15:26
173 schema:sdLicense https://scigraph.springernature.com/explorer/license/
174 schema:sdPublisher N8b212bb37b1f4e44a4fe689ee5ce255f
175 schema:sponsor https://www.grid.ac/institutes/grid.411198.4
176 https://www.grid.ac/institutes/grid.452970.d
177 schema:startDate 2016-12-01T00:00:00Z
178 schema:subjectOf sg:pub.10.1038/nrgastro.2013.31
179 sg:pub.10.1186/1471-230x-12-47
180 https://app.dimensions.ai/details/publication/pub.1074467244
181 https://doi.org/10.1002/ibd.21300
182 https://doi.org/10.1002/ibd.21595
183 https://doi.org/10.1002/ibd.22906
184 https://doi.org/10.1002/jbmr.5650100211
185 https://doi.org/10.1016/j.crohns.2011.02.008
186 https://doi.org/10.1016/j.jpsychores.2006.10.018
187 https://doi.org/10.1097/01.mib.0000437614.91258.70
188 https://doi.org/10.1097/mco.0b013e328357f623
189 https://doi.org/10.1152/ajprenal.00336.2004
190 https://doi.org/10.1155/2013/153818
191 https://doi.org/10.3748/wjg.v20.i17.4934
192 https://doi.org/10.5603/ep.2013.0012
193 https://doi.org/10.5946/ce.2013.46.4.317
194 schema:url https://clinicaltrials.gov/show/NCT02704624
195 sgo:license sg:explorer/license/
196 sgo:sdDataset clinical_trials
197 rdf:type schema:MedicalStudy
198 N8b212bb37b1f4e44a4fe689ee5ce255f schema:name Springer Nature - SN SciGraph project
199 rdf:type schema:Organization
200 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
201 rdf:type schema:DefinedTerm
202 sg:pub.10.1038/nrgastro.2013.31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041241127
203 https://doi.org/10.1038/nrgastro.2013.31
204 rdf:type schema:CreativeWork
205 sg:pub.10.1186/1471-230x-12-47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048740664
206 https://doi.org/10.1186/1471-230x-12-47
207 rdf:type schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1074467244 schema:CreativeWork
209 https://doi.org/10.1002/ibd.21300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039112127
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1002/ibd.21595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017307514
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1002/ibd.22906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019119236
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1002/jbmr.5650100211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017061708
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/j.crohns.2011.02.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040553044
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/j.jpsychores.2006.10.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038276653
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1097/01.mib.0000437614.91258.70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003898066
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1097/mco.0b013e328357f623 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045929804
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1152/ajprenal.00336.2004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053385973
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1155/2013/153818 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015525669
228 rdf:type schema:CreativeWork
229 https://doi.org/10.3748/wjg.v20.i17.4934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071370675
230 rdf:type schema:CreativeWork
231 https://doi.org/10.5603/ep.2013.0012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073037486
232 rdf:type schema:CreativeWork
233 https://doi.org/10.5946/ce.2013.46.4.317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019987573
234 rdf:type schema:CreativeWork
235 https://www.grid.ac/institutes/grid.411198.4 schema:Organization
236 https://www.grid.ac/institutes/grid.452970.d schema:Organization
 




Preview window. Press ESC to close (or click here)


...